Drag a card by its title · ⚙ to size, swap or remove

The company

Inhibrx Biosciences, Inc.

INBX · Nasdaq

Health CareBiotechnologyNot moving yet

INBX stood above a rising 150-day average in 45 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 7.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 2
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $11.8M
Insider sales, 12 months: $558K
Officials’ trades on record: 0
Institutions holding: 158 (+29)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 45 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8

Sale orders, 12 months5

Buyers · sellers3 · 1

Who	Did	Shares	Traded
Mark LappeChief Executive Officer	bought	2,470at $84.07	14 Oct 2026filed 14 Oct 2026
Mark LappeChief Executive Officer	bought	2,470at $85.00	14 Oct 2026filed 14 Oct 2026
Mark LappeChief Executive Officer	bought	100at $85.76	14 Oct 2026filed 14 Oct 2026
Mark LappeChief Executive Officer	bought	2,449at $84.07	14 Oct 2026filed 14 Oct 2026
Mark LappeChief Executive Officer	bought	2,451at $85.00	14 Oct 2026filed 14 Oct 2026
Mark LappeChief Executive Officer	bought	100at $85.76	14 Oct 2026filed 14 Oct 2026
Mark LappeChief Executive Officer	bought	1,500at $98.88	28 Sep 2026filed 28 Sep 2026
Mark LappeChief Executive Officer	bought	3,000at $101.70	28 Sep 2026filed 28 Sep 2026
Mark LappeChief Executive Officer	bought	3,324at $98.87	25 Sep 2026filed 28 Sep 2026
Mark LappeChief Executive Officer	bought	2,176at $99.60	25 Sep 2026filed 28 Sep 2026
Jon Faiz KayyemDirector	bought	5,000at $100.00	23 Sep 2026filed 23 Sep 2026
Jon Faiz KayyemDirector	bought	5,000at $100.00	16 Sep 2026filed 17 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders158+29 on the quarter

New · exited53 · 23

Reported value$1.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
MORGAN STANLEYadded · filed 13 Aug 2026	1,308,051$123.9M	+44,973+3.6%
PERCEPTIVE ADVISORS LLCreduced · filed 14 Aug 2026	1,297,763$123.0M	-144,944−10.0%
Sanofiunchanged · filed 28 Jul 2026	1,157,926$109.7M	00.0%
VIKING GLOBAL INVESTORS LPreduced · filed 14 Aug 2026	1,123,929$106.5M	-313,776−21.8%
HighTower Advisors, LLCadded · filed 5 Aug 2026	870,551$82.5M	+3510.0%
BANK OF AMERICA CORPadded · filed 14 Aug 2026	841,141$79.7M	+808,458+2473.6%
BlackRock, Inc.added · filed 7 Aug 2026	825,972$78.3M	+27,074+3.4%
Schonfeld Strategic Advisors LLCadded · filed 14 Aug 2026	697,586$66.1M	+442,759+173.7%
STATE STREET CORPadded · filed 7 Aug 2026	640,458$60.7M	+89,613+16.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	492,477$46.7M	+6,055+1.2%